Company intelligence / Profile preview

MY01

Montreal, Quebec, Canadamy01.io ↗

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

MY01 has developed and commercialized a continuous compartmental pressure monitoring device for the early and accurate diagnosis of acute compartment syndrome. The company’s device is FDA-cleared, CE-marked, and has received Breakthrough Device Designation. Clinical studies have demonstrated its safety and functionality in trauma patients at risk for developing compartment syndrome. As of March 2025, the company had shipped over 2,000 devices with use in more than 2,000 patients[1][4][5].

Therapeutic areas: Other
Modalities: DeviceDigital health platform (mobile app)MEMS-based sensor technology
Industry: Physiological Monitoring

Beyond the preview

Go deeper on MY01.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY01.

Explore the full profile